## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.6% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (37% of avg), momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($28.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting**
- Source: FOX 2 | 20251206T101500 | Bullish | Relevance: 99%
-  Ascentage Pharma announced the presentation of pivotal China registrational study data for Lisaftoclax at the 2025 American Society of Hematology (ASH) Annual Meeting. The data highlights Lisaftoclax's significant and durable clinical efficacy and manageable safety profile as a monotherapy for heavily pretreated BTK-refractory relapsed/refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients, including a 62.5% objective response rate and a median progression-free survival of 23.89 months. This data supported the drug's NDA approval in China, and Ascentage Pharma is conducting global Phase III studies to expand its indications.

**2. ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclaxâ€“Exposed Patients with Myeloid Malignances**
- Source: GlobeNewswire | 20251208T012125 | Bullish | Relevance: 98%
-  Ascentage Pharma announced promising data from a Phase Ib/II study of Lisaftoclax (APG-2575) in combination with azacitidine (AZA) for patients with newly diagnosed or venetoclax-exposed myeloid malignancies. The study showed preliminary evidence of Lisaftoclax overcoming venetoclax resistance with an overall response rate of 31.8% in venetoclax-exposed patients and an 80% ORR in newly diagnosed high-risk MDS/CMML, alongside a strong safety profile. These results highlight Lisaftoclax's potential as a new treatment option for AML and HR MDS.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Oppenheimer | $45 | $0 | 0% |
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |
| 2025-11-10 | BTIG | $50 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Oppenheimer | init | Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |
| 2025-11-10 | BTIG | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 244% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.9B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -1.8% to -4.6% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 44. Volume at 37% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.60% (CS: 19) | Weak |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 0.910x | Below |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $31.31
- **Stop Loss:** $28.63 (8.6% risk)
- **Target:** $33.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 186
- **Position Value:** $5,823.66
- **Portfolio %:** 5.82%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*